The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Abbvie; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Infinity Pharmaceuticals; Johnson & Johnson; Juno Therapeutics; MEI Pharma; miRagen; Sunesis Pharmaceuticals; Verastem
Honoraria - Ironwood Pharmaceuticals
A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).
 
Brian Koffman
No Relationships to Disclose
 
Betsy Dennison
Consulting or Advisory Role - Teva
 
Kaitlin Kennard
Consulting or Advisory Role - Abbvie; Gilead Sciences; Verastem
 
John C. Byrd
Consulting or Advisory Role - Acerta Pharma
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Janssen (Inst); Pharmacyclics (Inst)
 
John M. Pagel
Consulting or Advisory Role - Gilead Sciences; Pharmacyclics
 
Matthew Steven Davids
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Genentech; InCyte; Janssen; MEI Pharma; Merck; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); MEI Pharma (Inst); Pharmacyclics (Inst); Surface Oncology (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - TG Therapeutics
 
Chadi Nabhan
Employment - Cardinal Health
Leadership - Cardinal Health
Stock and Other Ownership Interests - Cardinal Health
 
Neil E. Kay
Consulting or Advisory Role - Agios; Celgene; CytomX Therapeutics; Gilead Sciences; Infinity Pharmaceuticals; MorphoSys
Research Funding - Acerta Pharma; Pharmacyclics/Janssen; Tolero Pharmaceuticals
 
Tanya Siddiqi
Consulting or Advisory Role - Juno Therapeutics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics; Kite, a Gilead company
 
Danielle M. Brander
Honoraria - Abbvie; Genentech; Teva; TG Therapeutics
Consulting or Advisory Role - Abbvie; Genentech/Abbvie; Novartis; Pharmacyclics; Teva; TG Therapeutics
Travel, Accommodations, Expenses - Abbvie; Teva; TG Therapeutics
Other Relationship - Novartis
 
Deborah Marie Stephens
No Relationships to Disclose
 
Brian Thomas Hill
Honoraria - Gilead Sciences; Pharmacyclics
Consulting or Advisory Role - Abbvie/Genentech; Novartis; Seagen
Research Funding - Abbvie (Inst); Karyopharm Therapeutics (Inst)
 
Javier Pinilla-Ibarz
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Speakers' Bureau - Pfizer; Takeda
 
Bruce D. Cheson
Consulting or Advisory Role - Abbvie; Acerta Pharma; Bayer; Morphosys; Pharmacyclics/Janssen; Roche/Genentech; Sunesis Pharmaceuticals; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Gilead Sciences (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
 
Steven T. Rosen
Honoraria - Celgene; Pharmacyclics; Valeant Pharmaceuticals International
Consulting or Advisory Role - Aileron Therapeutics; Celgene; Genentech; Seagen
Speakers' Bureau - AmerisourceBergen; The Scienomics Group; Xcenda
Research Funding - Celgene
 
Farrukh Tauseef Awan
Consulting or Advisory Role - Gilead Sciences; Novartis
Research Funding - Innate Pharma
 
Michael Y. Choi
Consulting or Advisory Role - Abbvie/Genentech; Novartis
Speakers' Bureau - Abbvie/Genentech; Gilead Sciences; Pharmacyclics
Research Funding - Abbvie (Inst); Pharmacyclics (Inst)
 
Anthony R. Mato
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Celgene; Janssen; Prime Oncology; TG Therapeutics
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); DTRM (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Regeneron (Inst); TG Therapeutics (Inst)